Introduction: Methicillin resistant Staphylococcus aureus (MRSA) emerged with increasing resistance to most of the antimicrobial agents used for treatment of infections. The incidence of hospital acquired MRSA varies from 25% in western part of India, to 50% in South India. There is need of new antimicrobial agents, as increase in resistance and spread of multi drug resistance among many pathogenic species. Tigecycline is a newer glycylcycline antimicrobial agent very active against bacteria resistant to other classes of antibiotics, including the quinolones & betalactams. Aims & Objective: To evaluate in vitro activity of Tigecycline against Methicillin resistant Staphylococcus aureus. Material and methods: A total of 50 MRSA were isolated from various clinical samples of patients attending to tertiary care hospital. The organisms were identified by conventional method and antimicrobial susceptibility testing was done by Kirby-Bauer disc diffusion method as per CLSI guidelines. Tigecycline MIC was determined by using E strips according to manufacturer’s instruction. Result: In our study all MRSA isolates were sensitive linezolid and teicoplanin. All MRSA isolates were inhibited by concentration of 0.5μg/ml of tigecycline. Most of strains in our study had MIC value less than 0.125μg/ml which was much below the US FDA cut offs for the susceptibility. Conclusion: Tigecycline is a potent anti microbial agent against MRSA. In the view of its excellent activity against MDR pathogens, it is prudent to reserve tigecycline for life threatening infections when other options fail.